Refractive Changes after Pharmacologic Resolution of Diabetic Macular Edema

详细信息    查看全文

• 作者：Gá ; bor G. Deá ; k ; MD ; Jan Lammer ; MD ; Sonja Prager ; MD ; Georgios Mylonas ; MD ; Matthias Bolz ; MD ; Ursula Schmidt-Erfurth ; MD ; ^{ursula.schmidt-erfurth@meduniwien.ac.at" class="auth_mail} ; on behalf of the Diabetic Retinopathy Research Group Vienna &lowast
• 刊名：Ophthalmology
• 出版年：May 2014
• 年：2014
• 卷：121
• 期：5
• 页码：1054-1058
• 全文大小：802 K

文摘

To determine precisely the mean change in refractive power induced by treatment in patients with diabetic macular edema (DME).

Design

Prospective, randomized study.

Participants

Fifty eyes of 50 consecutive patients with clinically significant macular edema receiving all 3 types of current state-of-the-art treatment with intravitreal antiedematous substances (ranibizumab, bevacizumab, or triamcinolone).

Methods

Patients were followed up at monthly intervals and were treated following a standardized pro re nata regimen according to protocol. Best-corrected visual acuity (BCVA) was determined by certified visual acuity examiners. The refractive power of the treated eyes was determined using a push-plus technique. The change in refraction between baseline and the visit when the macula was completely dry or when the central subfield thickness (CST) measured by optical coherence tomography had reached the thinnest level was analyzed.

Main Outcome Measures

Spherical equivalent refraction (SER) and CST.

Results

Fifty eyes of 50 patients received intravitreal therapy using ranibizumab (n = 11), bevacizumab (n = 20), or triamcinolone (n = 19). Mean BCVA was 0.33±0.23 logarithm of the minimum angle of resolution (logMAR) and mean CST was 492±130 渭m. The mean SER was 0.41±2.06 diopters (D) at baseline. The BCVA at the time of optimal retinal morphologic features was 0.24±0.2 logMAR, mean CST was 300±78 渭m, and mean change in SER was −0.01±0.46 D. Changes is BCVA and CST were statistically significant (P < 0.0001), but the SER change was not (P = 0.824).

Conclusions

Appropriate spectacle correction can be prescribed to patients with DME any time during ongoing therapy using antiedematous substances because resolution of retinal thickening is not associated with an increased risk of a myopic shift.